Synonym
PNU-101017; PNU101017; PNU 101017; U-101017; U 101017; U101017
IUPAC/Chemical Name
tert-butyl 7-chloro-5-((3R,5S)-3,5-dimethylpiperazine-1-carbonyl)imidazo[1,5-a]quinoline-3-carboxylate
InChi Key
JOJRKTAQXYPHBT-OKILXGFUSA-N
InChi Code
InChI=1S/C23H27ClN4O3/c1-13-10-27(11-14(2)26-13)21(29)17-9-19-20(22(30)31-23(3,4)5)25-12-28(19)18-7-6-15(24)8-16(17)18/h6-9,12-14,26H,10-11H2,1-5H3/t13-,14+
SMILES Code
O=C(C1=C2N(C=N1)C3=C(C=C(Cl)C=C3)C(C(N4C[C@@H](C)N[C@@H](C)C4)=O)=C2)OC(C)(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
442.94
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Zhong WZ, Williams MG, Branstetter DG. Toxicokinetics in drug development: an overview of toxicokinetic application in the development of PNU-101017, an anxiolytic drug candidate. Curr Drug Metab. 2000 Nov;1(3):243-54. Review. PubMed PMID: 11465047.
2: Hall ED, Fleck TJ, Oostveen JA. Comparative neuroprotective properties of the benzodiazepine receptor full agonist diazepam and the partial agonist PNU-101017 in the gerbil forebrain ischemia model. Brain Res. 1998 Jul 6;798(1-2):325-9. PubMed PMID: 9666160.
3: Im HK, Im WB, Pregenzer JF, Stratman NC, VonVoigtlander PF, Jacobsen EJ. Two imidazoquinoxaline ligands for the benzodiazepine site sharing a second low affinity site on rat GABA(A) receptors but with the opposite functionality. Br J Pharmacol. 1998 Apr;123(8):1490-4. PubMed PMID: 9605552; PubMed Central PMCID: PMC1565320.
4: Sethy VH, Wu H. The novel anxiolytic U-101017: in vitro and ex vivo binding profile and effect on cerebellar cGMP. Pharmacol Biochem Behav. 1997 Oct;58(2):609-13. PubMed PMID: 9300626.
5: Hall ED, Andrus PK, Fleck TJ, Oostveen JA, Carter DB, Jacobsen EJ. Neuroprotective properties of the benzodiazepine receptor, partial agonist PNU-101017 in the gerbil forebrain ischemia model. J Cereb Blood Flow Metab. 1997 Aug;17(8):875-83. PubMed PMID: 9290585.
6: Tang AH, Franklin SR, Carter DB, Sethy VH, Needham LM, Jacobsen EJ, Von Voigtlander PF. Anxiolytic-like effects of PNU-101017, a partial agonist at the benzodiazepine receptor. Psychopharmacology (Berl). 1997 Jun;131(3):255-63. PubMed PMID: 9203236.
7: Sethy VH, Wu H, Oostveen JA, Hall ED. Neuroprotective effects of the GABA(A) receptor partial agonist U-101017 in 3-acetylpyridine-treated rats. Neurosci Lett. 1997 May 30;228(1):45-9. PubMed PMID: 9197284.
8: Im HK, Im WB, Von Voigtlander PF, Carter DB, Murray BH, Jacobsen EJ. Characterization of U-101017 as a GABA(A) receptor ligand of dual functionality. Brain Res. 1996 Apr 1;714(1-2):165-8. PubMed PMID: 8861621.
